A photo of Jamie Capal.

Neurodevelopmental and Autism Specialist, Division of Neurology

Assistant Professor, UC Department of Pediatrics

513-636-4222

Board Certified

My Biography & Research

Biography

Dr. Capal’s clinical and research interests focus on children with autism spectrum disorders and related neurodevelopmental conditions. Current research projects include understanding the cognitive, behavioral, and language aspects of children with autism spectrum disorders and abnormal EEG but not always with concurrent clinical seizures. A natural extension of her research has led to interest in tuberous sclerosis complex (TSC), where autism, abnormal EEG, and seizures are frequent and interdependent. The genetic and molecular basis of TSC is well established, which provides an ideal platform for further investigation into the underlying mechanisms responsible and, in turn, discover new molecular-based targeted therapies. The TSC Clinic at Cincinnati Children’s Hospital Medical Center is the largest of its kind in the world, providing comprehensive, multidisciplinary clinical care to TSC patients of any age. This work led efforts that resulted in the first ever FDA-approved medical therapy for TSC in 2010 using the mTOR inhibitor everolimus. The long-term goal is to refine and apply these and next-generation therapies for patients with TSC.

Clinical Interests

Child neurology; developmental pediatrics; autism; tuberous sclerosis

Research Interests

Autism spectrum disorders; tuberous sclerosis

Academic Affiliation

Assistant Professor, UC Department of Pediatrics

Departments

Neurology, Tuberous Sclerosis, Neurology

Science Blog

My Locations

My Education

BA: Biology with honors, Ithaca College, Ithaca, NY, 2002.

MD: Albany Medical College, Albany, NY, 2002.

Internship: Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2006-2007.

Residency: Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2007-2008.

Resident/Fellow: Pediatric Neurodevelopmental Disabilities, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2008-1012.

My Publications

Impacting Development in Infants With Tuberous Sclerosis Complex: Multidisciplinary Research Collaboration. Williams, ME; Pearson, DA; Capal, JK; Byars, AW; Murray, DS; Kissinger, R; O'Kelley, SE; Hanson, E; Bing, NM; Kent, B; et al. American Psychologist. 2019; 74:356-367.

Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): Multicentre clinical experience. Krueger, DA; Capal, JK; Curatolo, P; Devinsky, O; Ess, K; Tzadok, M; Koenig, MK; Narayanan, V; Ramos, F; Jozwiak, S; et al. European Journal of Paediatric Neurology. 2018; 22:1066-1073.

mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders. Franz, DN; Capal, JK. Orphanet Journal of Rare Diseases. 2017; 12.

Tuberin Regulates Prostaglandin Receptor-Mediated Viability, via Rheb, in mTORC1-Hyperactive Cells. Li, C; Liu, X; Liu, Y; Zhang, E; Medepalli, K; Masuda, K; Li, N; Wikenheiser-Brokamp, KA; Osterburg, A; Borchers, MT; et al. Molecular cancer research : MCR. 2017; 15:1318-1330.

Utility of the Autism Observation Scale for Infants in Early Identification of Autism in Tuberous Sclerosis Complex. Capal, JK; Horn, PS; Murray, DS; Byars, AW; Bing, NM; Kent, B; Bucher, LA; Williams, ME; O'Kelley, S; Pearson, DA; et al. Pediatric Neurology. 2017; 75:80-86.

Improvement in Renal Cystic Disease of Tuberous Sclerosis Complex After Treatment with Mammalian Target of Rapamycin Inhibitor. Siroky, BJ; Towbin, AJ; Trout, AT; Schaefer, H; Thamann, AR; Agricola, KD; Tudor, C; Capal, J; Dixon, BP; Krueger, DA; et al. The Journal of Pediatrics. 2017; 187:318-322.e2.

Book Review: Developmental Assessment: Theory, Practice, and Application to Neurodisability Sonksen PM . Developmental Assessment: Theory, Practice, and Application to Neurodisability . London : Mac Keith Press , 2016 . 370 pp . $65.00 . ISBN: 978-1-909962-56-9 . Capal, JK. Journal of Child Neurology. 2017; 32:603-603.

Influence of seizures on early development in tuberous sclerosis complex. Capal, JK; Bernardino-Cuesta, B; Horn, PS; Murray, D; Byars, AW; Bing, NM; Kent, B; Pearson, DA; Sahin, M; Krueger, DA; et al. Epilepsy and Behavior. 2017; 70:245-252.

mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders. Franz, DN; Capal, JK. Orphanet Journal of Rare Diseases. 2017; 12.

Long-term treatment of epilepsy with everolimus in tuberous sclerosis. Krueger, DA; Wilfong, AA; Mays, M; Talley, CM; Agricola, K; Tudor, C; Capal, J; Holland-Bouley, K; Franz, DN. Neurology. 2016; 87:2408-2415.